Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.100
-0.090 (-2.82%)
Sep 15, 2026, 3:09 PM EDT - Market open
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $3.17M in the quarter ending June 30, 2026, a decrease of -39.13%. This brings the company's revenue in the last twelve months to $34.46M, down -19.07% year-over-year. In the year 2025, Voyager Therapeutics had annual revenue of $40.37M, down -49.53%.
Revenue (ttm)
$34.46M
Revenue Growth
-19.07%
P/S Ratio
5.70
Revenue / Employee
$244,390
Employees
141
Market Cap
191.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.37M | -39.63M | -49.53% |
| Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
| Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
| Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
| Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
| Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
| Dec 31, 2019 | 104.39M | 96.77M | 1,270.14% |
| Dec 31, 2018 | 7.62M | -2.52M | -24.82% |
| Dec 31, 2017 | 10.14M | -4.09M | -28.73% |
| Dec 31, 2016 | 14.22M | -3.11M | -17.96% |
| Dec 31, 2015 | 17.33M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| Tonix Pharmaceuticals Holding | 29.10M |
| Alpha Cognition | 15.26M |
| Armata Pharmaceuticals | 5.54M |
| Korro Bio | 2.38M |
| Oramed Pharmaceuticals | 2.00M |
VYGR News
- 6 days ago - Voyager Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 14 days ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Voyager Therapeutics reports Q2 EPS (40c), consensus (51c) - TheFly
- 5 weeks ago - Voyager Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Voyager Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Voyager Therapeutics presents six-month toxicology data for VY1706 - TheFly
- 2 months ago - Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 2 months ago - Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 - GlobeNewsWire